MedTrace Logo

Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.

NCT04779047 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-03-17

No results posted yet for this study

Summary

Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received different Antiviral and Anti Inflammatory Drugs.

Conditions

Interventions

DRUG

Remdesivir

Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.

DRUG

Hydroxychloroquine

Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.

DRUG

Tocilizumab

Tocilizumab 800 mg once.

DRUG

Lopinavir/ Ritonavir

Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.

DRUG

Ivermectin

Ivermectin 36 mg at day 1,3 and 6.

Sponsors & Collaborators

  • Beni-Suef University

    collaborator OTHER

  • October 6 University

    lead OTHER

Principal Investigators

  • Marian Boshra, PhD · Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-03-10
Completion
2021-04-05

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04779047 on ClinicalTrials.gov